2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 795

Frequency and Clinical Associations of Rare Antibodies in a Large Connective Tissue Disease Cohort
Abstract Number: 796

Demographic and Clinical Features of Systemic Sclerosis Patients with Anti-U1RNP Antibodies: A European Scleroderma Trials and Research (EUSTAR) Analysis
Abstract Number: 797

Absolute Reduction of Peripheral CD4+ Regulatory T Cells in Patients with Systemic Sclerosis and Its Restoration By Short-Term and Low Dose IL-2 Treatment
Abstract Number: 798

Predominant Fasciitis and Mild Intramuscular Edema on Muscle Magnetic Resonance Imaging in Scleroderma-Associated Myopathy
Abstract Number: 799

Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the Eustar Database
Abstract Number: 800

Assessment of Recent Evidence to Support Treatment Recommendations in Patients with SSc-ILD
Abstract Number: 801

Cardiac Autonomic Modulation at Rest and during Orthostatic Stress in Systemic Sclerosis Patients
Abstract Number: 802

Prognostic Significance of Bicaudal D2 Antibodies in Sistemic Sclerosis (SSc) Patients
Abstract Number: 803

Treating Interstitial Lung Disease and Skin Involvement in Systemic Sclerosis with Oral Versus Intravenous Cyclophosphamide: Preliminary Efficacy and Safety Data from 2 Randomized Clinical Trials and 1 Registry
Abstract Number: 804

Prevalence of Echocardiographic Abnormalities in Patients with Systemic Sclerosis
Abstract Number: 805

Diastolic Dysfunction in Scleroderma: An Investigation into Associated Risk Factors and Impact on Survival
Abstract Number: 806

Estradiol Levels Are Elevated in Older Men with Diffuse Cutaneous SSc and Are Associated with Decreased Survival
Abstract Number: 807

The Effects of DNA Methylation on Differential Expression in Dermal Fibroblasts from African-American Patients with Systemic Sclerosis
Abstract Number: 808

Mean Number of Nailfold Capillaries Is Associated with Disease Activity at 6 Months Follow-up in Systemic Sclerosis Patients
Abstract Number: 809

The Lymphangiogenetic Factors VEGF-C, CCL21 and Ang-2 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].